Vitlife

EXPLORING VYN201: A NEW HOPE FOR VITILIGO TREATMENT?

Share this article →
 
 
Close

Search articles

Exploring VYN201: A New Hope for Vitiligo Treatment?

 Posted on 12th September 2024  2 minute read

With limited treatment options available for vitiligo, VYN201, developed by VYNE Therapeutics, offers a new avenue of hope. This treatment is currently in Phase 2b trials and uses a new approach to target specific immune system pathways that play a role in vitiligo.

Understanding VYN201

VYN201 is classified as a pan-bromodomain BET inhibitor—a type of medication that targets specific proteins involved in controlling genes that influence inflammation and cell growth. By acting on these proteins, known as BET proteins, VYN201 helps to reduce inflammation which is believed to be a key factor in the destruction of melanocytes (the cells that give our skin its colour). This targeted action is designed to not only prevent the spread of white patches characteristic of vitiligo but also potentially restore colour to the affected areas.

Early Results

In a 16-week Phase 1b trial (initial testing phase), VYN201 led to ‘significant clinical improvement’ and was ‘well tolerated’, according to a press release by VYNE Therapeutics. Patients using the topical gel noticed changes in several important biomarkers linked to skin pigment production. The treatment led to a decrease in MMP-9 and an increase in several melanocyte-related transcription factors like SOX10, LEF1, beta-Catenin, and microphthalmia-associated transcription factor. These markers are crucial for the health and function of melanocytes, the cells responsible for skin color.

Patients applied the gel daily to a small area of affected skin, with doctors checking the progress through skin biopsies before and eight weeks after starting treatment.

Ongoing Research and Next Steps

VYN201 has now moved into a more advanced Phase 2b trial phase, where it will be tested in higher concentrations (1%, 2%, and 3%) on participants with both active and stable forms of nonsegmental vitiligo. This next stage is a double-blind study, meaning neither the participants nor the researchers know who receives the actual treatment versus a placebo, helping to eliminate bias in the results.

The main goal of this 24-week study is to see if the treated areas show at least a 50% improvement. Researchers will also track additional improvements over time, extending the study for another 28 weeks to gather more data.

David Domzalski, President and CEO of VYNE, remains optimistic about VYN201’s potential, citing its quick action and good safety profile from earlier trials. Results from this current study phase are expected by mid-2025.

Conclusion

VYN201 represents an exciting development in vitiligo treatment, potentially offering a more unique, effective, and targeted approach to managing this condition. As this trial progresses, many in the vitiligo community eagerly await the results, hopeful that VYN201 could provide a significant advancement in treatment options.

Please support our work! You've enjoyed 1 article this month and we hope you have found it useful. Our work is entirely funded by memberships and donations, so please consider joining our charity today and supporting our work.

Become a Member